Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2004
10/27/2004CN1539419A Compound preparation of reveratrol and application
10/27/2004CN1539417A Micromolecule chemical medicine-1 of new TATIN family
10/27/2004CN1539406A Fat lowered bathing powder and preparing method
10/27/2004CN1539304A Milk for lowering sugar and producing method
10/27/2004CN1172946C Flavone derivatives and preparing process and use thereof
10/27/2004CN1172929C Substituted indoles for modulating NFKB activity
10/27/2004CN1172705C Patent Chinese medicine for treating diabetes
10/27/2004CN1172683C Oral Selenium supplement agent using bimetallic oxide as carrier, and preparing process and use method thereof
10/27/2004CN1172672C Alpha-ketoamide multicatalytic protease inhibitors
10/26/2004US6809175 Cadherin derived growth factor and its use
10/26/2004US6809119 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
10/26/2004US6809115 Mixture has a synergistic, weight loss effect
10/26/2004US6809113 For therapy of arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis transplant rejection
10/26/2004US6809107 Neurodegenerative diseases
10/26/2004US6809106 Antiproliferation agents; such as 4-(2-methoxyphenoxy)-anilino-3-chloro-6,7-dimethoxyquinoline
10/26/2004US6809104 Comprises 6h-pyrido(4,3-b)carbazole-containing compounds for treatment of obesity, eating/anxiety/mood disorders and other diseases mediated by g-protein-coupled-receptors and melanin-concentrating hormone receptors
10/26/2004US6809095 Novel antitobesity and hypocholesterolemic compounds lower total cholesterol; increase high density lipoprotein (hdl) and decrease low denstiy lipoprotein
10/26/2004US6809094 N-fused hetercyclo-1,4- or -1,5- diazabicyclo derivatives; nicotinic receptor agonists; central nervous system (cns)
10/26/2004US6809092 1,3,4,5-tetrahydro-2h-2-benzazepin-2-yl derivatives; cysteine protease inhibitors
10/26/2004US6809090 Nitrogen monoxide synthase and/or lipidic peroxidation inhibitors
10/26/2004US6809089 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators
10/26/2004US6809077 A cyclic polypeptides; immunosuppressive anti-inflammatory activity, inhibiting antigen-induced inflammatory cell infiltration
10/26/2004US6808902 Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
10/26/2004US6808725 Food additive
10/26/2004US6808710 Contacting cell expressing pd-1 with binding agent; genetic transduction of negative signal
10/26/2004US6808703 Lactobacillus for use in he treatment of eating disorders and pancreatic defects
10/21/2004WO2004090118A1 Lactobacillus plantarum strain st-iii and its use in adjusting blood fat
10/21/2004WO2004089992A1 Modified acacia and use thereof
10/21/2004WO2004089967A1 HETEROARYL 5-THIO-β-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME
10/21/2004WO2004089966A1 METHOD FOR SELECTIVE PREPARATION OF HETEROARYL 5-THIO- β-D-ALDOHEXOPYRANOSIDE
10/21/2004WO2004089964A1 Lipid-regulating agent and use thereof
10/21/2004WO2004089951A1 Imidazopyridine derivatives having an affinity for melanocortin receptors
10/21/2004WO2004089945A1 Rosiglitazone derivatives as antidiabetic agents
10/21/2004WO2004089936A1 Heteroarylsulfonanilide derivative and medicinal composition containing the same
10/21/2004WO2004089919A1 Cyclohexanecarboxamido derivative
10/21/2004WO2004089918A1 Heteroaromatic pentacyclic compound and medicinal use thereof
10/21/2004WO2004089917A2 Process for resolving 2,4-diamino-3,6-dihydro-1,3,5-triazines, useful for the treatment of disorders associated with insulin resistance syndrome
10/21/2004WO2004089916A1 11-phenyl-dibenzodiazepine derivatives as rxr-antagonists
10/21/2004WO2004089899A1 Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
10/21/2004WO2004089896A1 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
10/21/2004WO2004089895A1 Process for the preparation of amorphous calcium salt of atorvastatin
10/21/2004WO2004089471A2 NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
10/21/2004WO2004089470A2 New amide derivatives and pharmaceutical use thereof
10/21/2004WO2004089416A2 Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
10/21/2004WO2004089412A1 Specific nad(p)h oxidase inhibitor
10/21/2004WO2004089399A1 Novel uses of rfrp and ot7t022
10/21/2004WO2004089386A1 Antiobestic agent using hen’s egg antibody against digestive enzymes
10/21/2004WO2004089380A2 Pharmaceutical use of fused 1,2,4-triazoles
10/21/2004WO2004089367A1 Pharmaceutical use of substituted 1,2,4-triazoles
10/21/2004WO2004089282A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/21/2004WO2004089117A1 Food and drink having reduced digestibility and process for producing the same
10/21/2004WO2004071402A3 STABLE PHARMACEUTICAL DOSAGE FORM COMPRISING HMG-CoA REDUCTASE INHIBITOR
10/21/2004WO2004065380A8 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
10/21/2004WO2004064856A3 Proteins involved in the regulation of energy homeostasis
10/21/2004WO2004009556A9 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
10/21/2004WO2003096980A3 Bicyclic modulators of androgen receptor function
10/21/2004WO2003062241A8 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function
10/21/2004WO2003045228A3 Methods for treating autoimmune disorders, and reagents related thereto
10/21/2004US20040210080 3-(oxo, oxime, hydrazone, or alkylidene)-fluorene derivatives; can be synergistically combined with other anticarcinogenic, anticholesterol, anxiolytic agents, antidepressants or enzyme inhibitors; bone disorders
10/21/2004US20040210079 selective monoamine oxidase B inhibitors; neurodegenerative diseases; Alzheimer's Disease
10/21/2004US20040210052 Efficient synthesis of 5-heteroatom-containing-pyrazoles
10/21/2004US20040210042 Polypeptides relating to signal transfer of advanced glycation end product receptor
10/21/2004US20040209963 dispersing in an aqueous phase a solution of an active substance or composition in dimethylether or in a C4-hydrocarbon or mixtures thereof in super- or nearcritical state, decompressing mixture and separating dispersion from gaseous solvent; dispersed particles are in micro or nano size range
10/21/2004US20040209943 e.g., N-(3-Cyano-4,5-dimethyl-thiophen-2-yl)-2,2-diphenyl-acetamide;3-Methyl-2-phenyl-pentanoic acid-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-amide; or N-(3-Cyano-6-methanesulfonyl-4,5,6,7-tetrahydro-thieno [2,3-c]pyridin-2-yl)-2,2-diphenyl-acetamide;
10/21/2004US20040209941 administering inhibitor of the renin-angiotensin system such as quinapril; for AIDS patients under retroviral therapy
10/21/2004US20040209938 Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them
10/21/2004US20040209936 Compounds that modulate PPAR activity and methods of preparation
10/21/2004US20040209935 Pyrazole-derived kinase inhibitors and uses thereof
10/21/2004US20040209932 1,3-substitued cycloalkyl derivatives having acidic, mostly heterocyclic groups; processes for their preparation and their use as pharmaceuticals
10/21/2004US20040209920 Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
10/21/2004US20040209914 Aromatic sulfone hydroxamic acids and their use as protease inhibitors
10/21/2004US20040209908 New derivatives of hydantoins, thiohydantoins, pyrimidinediones and thioxopyrimidinones, their preparation processes and their use as medicaments
10/21/2004US20040209901 substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds, e.g., 8-(2,6-Difluoro-phenyl)-4-(4-fluoro-2-methyl-phenyl)-2-(2-hydroxy-1-hydroxymethyl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; CSBP/p38 kinase inhibitors.
10/21/2004US20040209900 administering pentoxifylline to reduce abnormal accumulation of fat in either the cervico-thoracic area or in the abdominal region; reducing facial wrinkles
10/21/2004US20040209894 e.g., 1-(4-chloroanilino)-4-[2-(pyridin-3-yl)-ethyl]-isoquinoline and 5-[4-(tert-butyl)-anilino]-8-[(6-methoxy-pyridin-3-yl)-methyl]-[1,6]naphthyridine
10/21/2004US20040209891 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV
10/21/2004US20040209890 Polyhydroxyalkylpyrazine derivatives, their preparation and medicaments comprising them
10/21/2004US20040209874 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
10/21/2004US20040209870 contain 5-HT ligands used to treat central nervous system disorders
10/21/2004US20040209868 Substituted indoles
10/21/2004US20040209866 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders
10/21/2004US20040209848 Administering to a patient (11 alpha , 15 alpha , 13E)-9-oxo-11,15-dihydroxy- 16-(3-methoxymethylphenyl)-17, 18, 19, 20-tetranor-5-thiaprost-13-enoic acid methyl ester, or cyclodextrin clathrate for treating osteoporosis
10/21/2004US20040209847 treating and preventing a variety of diseases and conditions such as aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic retinopathy, dyslipidemia, dyslipoproteinemia, hypertension, impotence, insulin resistance, peroxisome proliferator activated receptor associated disorders
10/21/2004US20040209825 Inhibition by 3-deoxyflavonoids of T-lymphocyte activation and therapies related thereto
10/21/2004US20040209824 administering a sulfamate compound (topiramate) to mammals
10/21/2004US20040209819 Administering to the chronic skin ulcer an effective amount of a polypeptide of between 14 to 23 amino acids in length, cotnains a thrombin receptor binding domain of the sequence Arg-Gly-Asp-Ala (SEQ ID NO.: 7) and a serine esterase conserved sequence
10/21/2004US20040209816 Treatment for diabetes
10/21/2004US20040209813 Caspase inhibitors for inhibiting blood cell proliferation and for treating autoimmune diseases
10/21/2004US20040209801 administering gastrin/(cholecystokinin (CCK) receptor ligand and a factor for complementing gastrin for islet neogenesis therapy; sustained release; for expanding a functional beta cell mass of pancreatic islet transplants; reduces amount of stem cells necessary for treatment; kits
10/21/2004US20040209798 biodrugs for treatment of lung cancer, glioma, anorexia, hypothyroidism, hyperaldosteronism, H. pylori proliferation, acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites
10/21/2004US20040209342 Comprises nucleotide sequences coding hydrolase for use in identifying modulators for treatment of diabetes and inflammatory diseases
10/21/2004US20040208859 Bile acid absorbent/adsorbent
10/21/2004DE102004010921A1 Feste Oraldosierungsform von Metformin und Glyburid sowie ein Verfahren zu Ihrer Herstellung Oral solid dosage form of metformin and glyburide and a process for their preparation
10/21/2004CA2843439A1 Reversible pegylated drugs
10/21/2004CA2521997A1 Antiobestic agent using hen's egg antibody against digestive enzymes
10/21/2004CA2521879A1 Process for resolving amines that are useful for the treatment of disorders associated with insulin resistance syndrome
10/21/2004CA2521830A1 Heteroaromatic pentacyclic compound and medicinal use thereof
10/21/2004CA2521692A1 Modified acacia and use thereof
10/21/2004CA2521337A1 11-phenyl-dibenzodiazepine derivatives as rxr-antagonists
10/21/2004CA2520855A1 Imidazopyridine derivatives as melanocortin receptor agonists
1 ... 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 ... 1298